[Active surveillance for the secondary prevention of prostate cancer].

[1]  John Kurhanewicz,et al.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer , 2012, BJU international.

[2]  P. Carroll,et al.  Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. , 2011, The Journal of urology.

[3]  S. Greenfield,et al.  Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.

[4]  O. Cussenot,et al.  From active surveillance to the concept of secondary prevention. , 2011, European urology.

[5]  A. Partin,et al.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Matthew R. Cooperberg,et al.  Inaccuracies in assignment of clinical stage for localized prostate cancer , 2011, Cancer.

[7]  Kirsten L. Greene,et al.  Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Soloway,et al.  Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. , 2010, European urology.

[9]  A. Evans,et al.  ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging , 2010, BJU international.

[10]  C. Abbou,et al.  63 THE ROLE OF BIOPSY CORE NUMBER IN SELECTING PROSTATE CANCER PATIENTS FOR ACTIVE SURVEILLANCE , 2010 .

[11]  A. Hoznek,et al.  The role of biopsy core number in selecting prostate cancer patients for active surveillance. , 2009, European urology.

[12]  Dirk F Moore,et al.  Outcomes of localized prostate cancer following conservative management. , 2009, JAMA.

[13]  Michael Seitz,et al.  Insignificant prostate cancer and active surveillance: from definition to clinical implications. , 2009, European urology.

[14]  Laurent Lemaitre,et al.  Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance , 2009, Current opinion in urology.

[15]  P. Carroll,et al.  Pathological outcomes of candidates for active surveillance of prostate cancer. , 2009, The Journal of urology.

[16]  B. Guillonneau,et al.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. , 2008, The Journal of urology.

[17]  M. Cooperberg,et al.  Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.

[18]  P. Carroll,et al.  Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? , 2008, Radiology.

[19]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[20]  D. Dearnaley,et al.  Does active surveillance for men with localized prostate cancer carry psychological morbidity? , 2007, BJU international.

[21]  M. Wallace,et al.  Watching, waiting and uncertainty in prostate cancer. , 2007, Journal of clinical nursing.

[22]  S. Andersson,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[23]  J. Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[24]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[25]  Janet L. Stewart,et al.  Uncertainty Intervention for Watchful Waiting in Prostate Cancer , 2004, Cancer nursing.

[26]  L. Holmberg,et al.  Natural history of early, localized prostate cancer. , 2004, JAMA.

[27]  P. Boyle,et al.  The epidemiology of prostate cancer. , 2003, The Urologic clinics of North America.

[28]  J. Köllermann,et al.  Nondetected Tumor (pT0) after Prolonged, Neoadjuvant Treatment of Localized Prostatic Carcinoma , 2000, European Urology.

[29]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Tammela,et al.  Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.

[31]  T. Wilt,et al.  The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. , 2009, Contemporary clinical trials.